Onco-Innovations Partners with Dalton Pharma for PNKP Isotope Synthesis

Onco-Innovations Limited has announced a partnership with Dalton Pharma Services for the custom synthesis of a labelled isotope of its Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor. The PNKP technology has shown potential in increasing survival rates in PTEN-deficient colorectal cancer mice. By using Dalton's services, Onco aims to advance its IND-enabling animal model research.

The study conducted in June 2021 demonstrated that the PNKP inhibitor increased median survival in treated mice from 23 to 60 days. This development highlights the therapeutic potential of PNKP inhibitors by targeting cancer cells and minimizing toxicity to healthy tissues.

Onco's partnership with Dalton signifies a critical step in advancing ADME studies, thereby supporting further development and potential clinical trials. The collaboration aims to bolster Onco's efforts in cancer research and treatment through targeted nanoparticle delivery systems.